Meeting
2022 ASCO Annual Meeting
Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.
Presenter
Lacey J. Padron, PhD
Parker Institute for Cancer Immunotherapy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Can We Begin to Predict Responders to Targeted Therapy in Gastrointestinal Cancer?
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03214250
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4010)
DOI
10.1200/JCO.2022.40.16_suppl.4010
Abstract #
4010
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.
Speaker: Efrat Dotan, MD
Speaker: Scott E. Eggener, MD
Videos & Slides
2023 ASCO Annual Meeting
Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.
Speaker: Wungki Park, MD, MS
Speaker: Panel Discussion